Podcasts about karolinska institutet

I det här avsnittet pratar Kajsa med psykoterapeuten och författaren Evelina Linder om ätstörningar hos barn och unga. Evelina har under många år arbetat med barn och unga med ätstörningar och hon utbildar och handleder personal inom den specialiserade ätstörningsvården. Under samtalet berättar Evelina bland annat om hur föräldrar kan stötta sitt sjuka barn och vilket stöd som är rimligt att förvänta sig av skolan och vården. Vidare diskuteras vad Socialstyrelsens nya riktlinjer säger om vilka insatser som är effektiva. Och sist men inte minst - hur man ska orka som förälder. Länkar:Föräldraguiden vid ätstörningar https://atstorning.se/(Centre for Eating Disorders Innovation (CEDI) vid Karolinska Institutet i Stockholm, där också Kunskapscentrum för ätstörningar (KÄTS) ingår. https://www.friskfri.se/ Nationella riktlinjer: ätstörningar Hosted on Acast. See acast.com/privacy for more information.

Covid-19 har på många sätt präglat våra liv under de senaste åren, och nya forskningsresultat fortsätter att ge oss insikt i hur immunförsvaret agerar i samband med viral infektion. Ett exempel på detta är den studie som Philip Curman, specialist i dermatologi vid Karolinska Universitetssjukhuset i Solna, disputerad inom genetiska hudsjukdomar och forskare inom dermatologisk epidemiologi vid Karolinska Institutet, nyligen publicerade i The Journal of Allergy and Clinical Immunology tillsammans med ett internationellt forskarlag.I studien, som baserades på den amerikanska elektroniska hälsodatabasen TriNetX, undersökte man sambandet mellan covid-19-infektion och typ 2-inflammatoriska sjukdomar, och fann en markant ökad risk för personer som haft covid-19 att utveckla astma, kronisk bihåleinflammation och/eller allergisk rinit. Däremot såg man ingen ökad risk för typ 2-inflammatoriska sjukdomar i huden, som atopisk dermatit, eller i matstrupen i form av eosinofil esofagit. En ännu tydligare skillnad framträdde vid jämförelse med individer som vaccinerats mot covid-19, vilket indikerar att vaccination inte bara skyddar mot infektion i sig, utan även verkar ha en viss förebyggande effekt mot vissa följdsjukdomar i luftvägarna. I detta avsnitt diskuterar han studiens upplägg och resultat, potentiella begränsningar och såväl planerade som pågående forskningsprojekt inom typ 2-inflammation, som förhoppningsvis kan bidra till ökad förståelse för immunaktivering och sjukdomsutveckling.Läs mer om den aktuella studien och pågående och kommande forskningsprojekt här:COVID-19 infection raises respiratory type 2 inflammatory disease risk, whereas vaccination is protective - ScienceDirectPhilip Curman | Karolinska Institutet

Welcome to Ozempic Weightloss Unlocked, the podcast that unpacks how this medication is reshaping health, lifestyle, and the future of weight management.Ozempic is a brand name for semaglutide, a medication originally approved to treat type two diabetes. It mimics a gut hormone that helps the pancreas release insulin, lowers blood sugar, slows stomach emptying, and signals the brain to feel full sooner. The result for many people is significant weight loss, which is why a higher dose of the same drug is sold separately for obesity under the name Wegovy, according to the United States Food and Drug Administration and the National Institutes of Health.Because of this dual effect on blood sugar and appetite, Ozempic has become a cultural phenomenon. Listeners hear about it from celebrities, social media, and even coworkers, but medical experts keep stressing one key point. These are prescription drugs meant for people with type two diabetes or with obesity and related health risks, not quick fixes for casual weight loss. Major medical groups such as the American Diabetes Association and the Obesity Society are pushing to protect access for patients who truly need them.Recently, attention has shifted to what happens beyond the number on the scale. Some people lose not only fat but also muscle, which can affect strength, mobility, and metabolism. Researchers at Karolinska Institutet and Stockholm University, writing in the journal Cell, report a new tablet treatment that increases fat burning and improves blood sugar while preserving muscle mass, and it works very differently from Ozempic. Instead of acting on appetite in the brain, it targets skeletal muscle directly, and early trials suggest it may be used alone or even combined with a drug like Ozempic in the future.At the same time, the competition in obesity medicine is heating up. Eli Lilly has developed a so called triple hormone drug called retatrutide that activates three receptors instead of one. Eli Lilly and coverage from outlets like ABC News report that in a large trial of people with obesity and knee osteoarthritis, participants on the highest dose lost nearly twenty nine percent of their body weight on average and saw a big drop in knee pain. While retatrutide is still in clinical trials and not yet approved, it shows how the field is racing to go beyond the results seen with Ozempic alone.For listeners, this rapid progress brings both excitement and responsibility. These medications can improve blood sugar, reduce cardiovascular risk, and help treat diseases linked to excess weight, but they can also cause nausea, vomiting, diarrhea, and in some cases gallbladder or pancreatic issues. Long term use may require monitoring of muscle mass, nutrition, and mental health. Physicians are now talking more about pairing these drugs with resistance training, adequate protein, and psychological support so that weight loss does not come at the cost of strength or well being.Ozempic has also raised bigger questions. Who should get access when supplies are limited. How will insurance handle long term therapy for what is often a chronic condition. And what happens if a person stops the medication and the hunger comes back. Early data suggest that for many, maintaining results may require ongoing treatment, much like blood pressure medicine.On Ozempic Weightloss Unlocked, we will keep tracking all of this. From new trials and pill based options, to combination therapies, insurance changes, and real world stories of how life looks on and off these medications, our goal is to give you clear, balanced information so you can have better conversations with your own health care team.Thank you for tuning in, and remember to subscribe so you never miss an update on the evolving world of Ozempic and weight loss science.This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Gaston är 14 och märker att han plötsligt är så morgontrött att han inte kan ta in vad någon säger. Under tonåren förskjuts dygnsrytmen. Lyssna på alla avsnitt i Sveriges Radios app. I tonåren blir det ofta svårt att komma upp på morgonen. Flera högstadieskolor testar just nu att senarelägga skolstarten. Eleverna får börja och sluta skoldagen en timme senare. - Många jublade när vi införde det. Jag är positiv, jag tror på det här, jag upplever att det blivit lugnare i klassrummet, säger högstadieläraren Júlía Sigurdardóttir.Veckans avsnitt handlar om dygnsrytm, sovmorgnar, tupplurar och om hur du kan göra för att återhämta dig från sömnbrist. Medverkande: John Axelsson, professor och sömnforskare vid Karolinska Institutet och Stocholms universitetLi Åslund, psykolog och forskare aktuell med boken “Tonårssömn”Malin Jakobsson, forskare som just nu studerar hur en timmes senare skolstart påverkar ungdomarna vid Hälsohögskolan, Jönköping. Júlía Sigurdardóttir, högstadielärareElin Kimland, utredare på LäkemedelsverketProgramledare: Ulrika Hjalmarson NeidemanProducent: Stina NäslundReporter: Olivia SandellBilden är en genrebild. Foto: Ulrika Hjalmarson Neideman.

Welcome to Ozempic Weightloss Unlocked, the show where we unpack how this powerful medication is reshaping medicine, health, and everyday life.Today we are diving into the very latest science on semaglutide, the drug sold as Ozempic for diabetes and Wegovy for obesity, and what new research means for listeners who are using it or thinking about it.A new real world study in the journal Current Medical Research and Opinion followed people on once weekly semaglutide for two full years. Researchers found that on average, patients lost about thirty nine pounds, or nearly seventeen percent of their body weight, and most kept that weight off over the full twenty four months. People also saw improvements in blood pressure, cholesterol, blood sugar, and many moved from prediabetes or diabetes back to normal blood sugar levels. That is important, because it confirms that Ozempic is not just a quick fix but can be part of long term weight management when it is continued and combined with lifestyle changes.At the same time, doctors are getting clearer about downsides. A recent analysis from researchers in Utah, reported by Ladbible, warned that Ozempic related weight loss can come with a drop in lean mass, including muscle, of around ten percent. That is less loss than some earlier crash diets have caused, but it still matters. Losing muscle can weaken strength, slow metabolism, and be especially risky for older adults. Experts now stress pairing Ozempic with enough protein, resistance exercise, and medical follow up to protect muscle.For older listeners, the Association of American Medical Colleges reports that trials suggest these drugs can be safe and effective after age sixty five, but that adults over seventy five were rarely studied. Clinicians are urging extra caution in seniors because they are more prone to side effects like nausea, dehydration, and muscle loss, and they may already be on multiple medications.Researchers are also uncovering surprising new uses. Memorial Sloan Kettering Cancer Center reports that glucagon like peptide drugs such as Ozempic may help people with obesity reduce their risk of several cancers linked to excess body fat, including breast and colon cancer. In an early study in breast cancer patients, these medications helped counteract the weight gain that often comes with treatment, which could improve long term heart and cancer outcomes if confirmed in larger trials.Scientists are even exploring effects on brain health. Imperial College London recently showed that another drug in the same family, called liraglutide, slowed brain shrinkage and cognitive decline in people with Alzheimer disease over one year. Patients on liraglutide had almost fifty percent less brain volume loss in key memory areas compared with placebo, and their thinking declined about eighteen percent more slowly. While this was not Ozempic itself, it suggests this whole class of drugs might play a future role in protecting the brain, and large phase three trials are now underway.There is also growing attention on mental health. Think Global Health highlights that when people lose even a modest amount of weight and improve metabolic health, their risk of depression and anxiety often falls. Some patients report better mood and fewer food cravings on Ozempic, while a small number describe emotional blunting or worries about identity after major weight loss. Regulators in Europe have examined rare reports of suicidal thoughts, but the United States Food and Drug Administration has said current evidence does not show a clear causal link. Still, it is essential for anyone on these medications to check in regularly with their care team about mood and mental health, not just the number on the scale.Finally, researchers are already working on what might come next. Scientists at Karolinska Institutet in Sweden recently reported a new experimental pill that burns fat by acting directly on muscle metabolism instead of appetite. In early human trials it improved blood sugar and body composition without reducing appetite or muscle mass. If it proves safe and effective, it may one day be used alone or together with drugs like Ozempic to achieve weight loss with fewer side effects.Taken together, the latest science tells us this. Ozempic and related medications can deliver major, sustained weight loss and improve heart and metabolic health. They may lower risks tied to obesity, from diabetes to some cancers, and could even have future roles in brain health. But they are not magic. Protecting muscle, supporting mental health, tailoring treatment to age, and combining medication with nutrition, movement, and sleep are all crucial.Thank you for tuning in to Ozempic Weightloss Unlocked. If you found this episode helpful, be sure to subscribe so you never miss the latest updates on Ozempic, weight loss, and health.This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Digital integritet i algoritmernas tid – hur övervakas vi på jobbet? En av vår tids mest avgörande framtidsfrågor för arbetslivet och arbetsmiljön är hur vi skyddar människan i en alltmer övervakad arbetsvardag. AI förändrar inte bara vad vi gör – utan hur arbetslivet styrs. I takt med att tekniken blir smartare blir medarbetarna allt mer övervakade. När AI-system börjar fatta beslut om arbetstid och ersättning, lär sig läsa våra ansiktsuttryck, tolka våra känslor och analysera våra prestationer i realtid – vad händer med den personliga integriteten i arbetslivet? Det här är en podd av Futurions studiosamtal Digital integritet i algoritmernas tid som spinner vidare på Futurions rapport Tyst kontroll, högt pris.  Medverkande i podden/studiosamtalet: Fia Ewald, rådgivare och expert inom informationssäkerhet och integritet. Med lång erfarenhet från både offentlig sektor och säkerhetsområdet ger Fia en skarp bild av teknikutvecklingen – och de risker som följer med ökad datainsamling och automatiserat beslutsfattande. Fia satt med som expert i integritetsutredningen 2016. Ruben Lind, doktorand i arbetsmedicin vid Karolinska Institutet. Ruben  forskar om effekter av algoritmisk arbetsledning på hälsa, säkerhet och välbefinnande inom programmet ALGOSH. (Algorithmic management at work – challenges, opportunities, and strategies for occupational safety and health and wellbeing) Susanna Kjällström, teamchef och förbundsjurist på Unionen. Susanna har arbetat som förbundsjurist i 18 år med särskilt expertis inom mänskliga rättigheter och dataskydd. Hon har även skrivit en bok om integritet i arbetslivet tillsammans med Erik Grahn. Ann-Therése Enarsson, vd Tankesmedjan Futurion. Ann-Therése sätter människan i centrum när vi pratar om teknik och arbetsliv. Lyfter frågor om makt, arbetsmiljö och trygghet i en tid där algoritmer blir chefer och medbestämmandet pressas tillbaka. Moderator: Rebecka Prentell, projektledare Futurion Rebecka är en erfaren moderator med många års erfarenhet av operativt politiskt ledarskap från fackföreningsrörelsen, civilsamhället och ungdomspolitiken.

I detta faktaspäckade avsnitt gästas vi av Erik Iwarsson, läkare inom klinisk genetik, för att reda ut begreppen kring ett ämne som blir alltmer aktuellt: genetisk testning. Vad är egentligen skillnaden på att testa embryon för ärftliga sjukdomar (PGT-M/SR) och att screena för kromosomavvikelser (PGT-A)? Vi dyker ner i varför PGT-A inte är tillåtet i Sverige idag och vad den nya SBU-rapporten säger om metodens effekt på "time to pregnancy". Erik förklarar även genetiken bakom upprepade missfall, hur NIPT-test fungerar och de etiska frågorna kring att screena donatorer. Ett otroligt lärorikt samtal som ger en djupare förståelse för både de medicinska möjligheterna och de svåra avvägningarna inom IVF-vården. Erik Iwarsson  är Docent i Medicinsk genetik vid Karolinska Institutet och överläkare vid Klinisk genetik, Karolinska Universitetssjukhuset. Avsnittet görs i samarbete med Merck. Ladda gärna ner deras patientbroschyrer via länken på Mercks Instagram "fertilitetsträdet" för mer kunskap.

Marta Paterlini"La pelle che pensa"Il tatto come linguaggio universale, tra filosofia, neuroscienze e tabù sociali.Codice Edizioniwww.codiceedizioni.itSottovalutato e dato per scontato, cos'è successo al tatto, l'atto più semplice e antico dell'umanità? Il tatto nasconde un mondo: è un linguaggio universale, un dialogo tra cervello e pelle, un atto di cura e una forma di resistenza in un'epoca in cui i corpi si allontanano. Centrale nei miti dell'Odissea e indagato dalla filosofia fin da Aristotele, il tatto è finalmente studiato dalle neuroscienze, che ne mostrano l'essenza: dalle carezze che alleviano il dolore nelle cure palliative alle fibre nervose che trasformano un massaggio in benessere; dalla fragilità di chi si chiude al contatto alla fame di pelle che genera disagio mentale. Nella società il tatto riflette visioni diverse del corpo, dell'identità e della cultura: la pelle sintetica della robotica, il tocco sociale, l'evoluzione dei saluti, le manipolazioni mediche, le politiche no-touch nelle scuole, fino alle ricerche sui canali Piezo del premio Nobel Ardem Patapoutian e alle fibre C-tattili del tocco affettivo. Sono questi i tasselli del mosaico che la neuroscienziata e divulgatrice Marta Paterlini ricompone in La pelle che pensa, mostrando come il tatto sia oggi sospeso tra tabù e necessità, paura del contatto e disperato bisogno di connessione. Perché toccare è curare, parlare, esistere.«In un mondo sempre più digitale, dove le relazioni spesso si sviluppano attraverso uno schermo, la pelle ci ricorda la magia del contatto diretto. Ogni abbraccio, ogni carezza, ogni stretta di mano è un ponte che ci avvicina, superando barriere culturali e linguistiche. Il tatto è uno dei primi canali attraverso cui esploriamo la realtà e instaura connessioni profonde tra gli individui. Ogni abbraccio sembra diverso perché tutti quelli che abbracciamo occupano spazio nel mondo in un modo diverso». Marta PaterliniMarta PaterliniNeurobiologa e giornalista scientifica freelance. Ha lavorato presso il Laboratory of Molecular Biology di Cambridge, in Inghilterra, e alla Rockefeller University di New York. Attualmente è senior scientist presso il Karolinska Institutet di Stoccolma, dove vive. Collabora con “Science”, “Nature” e “The Lancet”.Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/il-posto-delle-parole--1487855/support.IL POSTO DELLE PAROLEascoltare fa pensarehttps://ilpostodelleparole.it/

The importance of odors to your taste buds might be greater than you think. Putu Agus Khorisantono, postdoctoral researcher at the Karolinska Institutet, delves into this. I am a cognitive and behavioural neuroscientist based in the Department of Clinical Neuroscience (Psychology Division) of Karolinska Institutet, with a background in statistics, functional neuroimaging and neuroeconomics. My […]

Samtal med Peter Ueda, finalist till SNS-priset 2025.  Peter Ueda är läkare och docent i epidemiologi vid Karolinska Institutet och en välkänd forskare inom sexuell hälsa. I boken Man går sin egen väg utforskar han incel-rörelsens framväxt och vad det säger om vår tids normer kring intimitet, maskulinitet och social samhörighet. Hans arbete har väckt stor internationell uppmärksamhet och publicerats i ledande vetenskapliga tidskrifter samt i internationell dagspress. Under föreläsningen berättar han om sin forskning om sexuell inaktivitet och om de manliga subkulturer som vuxit fram som en följd av fenomenet. Juryn motiverade sitt val av Peter Ueda som finalist med att han "har förmågan att tillgängliggöra sin forskning på ett sätt som bidrar till att stötta individer och beslutsfattare att fatta mer välinformerade beslut. Peter Ueda är en tydlig förebild för yngre forskare i sitt sätt att bedriva och förmedla forskning." Samtalet genomförs inom ramen för SNS prisföreläsningar och modereras av Gabriella Chirico Willstedt, forskningsledare och medlemschef, SNS.

Det vanligaste försöksdjuren på Karolinska Institutet är möss, råttor och zebrafiskar, ibland förekommer också försök på primater. Hör forskarna förklara varför det ännu inte går att ersätta alla försöksdjur med alternativa metoder. Vi pratar om de tre R:en som står för reduce-refine-replace, och så blir det reportage från zebrafiskfaciliteten.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: It's World Diabetes Day and we have a LOT of news to get to! Daily oral insulin tested to prevent T1D, mothers and sons and a T1D link, stem cell updates, Tandem Android news, Omnipod's workplace campaign and more! Find out how to submit your Community Commercial Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. It's world diabetes day! It is marked every year on 14 November, the birthday of Sir Frederick Banting, who co-discovered insulin along with Charles Best in 1922.   WDD was created in 1991 by International Diabetes Federation (IDF) and the World Health Organization and became an official United Nations Day in 2006 with the passage of United Nations Resolution 61/225. There will be a ton of stuff in your feeds today and that's great! I'm going to keep this to a pretty normal in the news episode.. although I do have my own World Diabetes Day announcement – I want YOUR community commercials. You could have an ad for your event or your blog or your project right here! There's a post on the website explaining it all and I'll come back at the end of the episode and tell you more. XX The Primary Oral Insulin Trial (POInT) is the first large-scale clinical trial to test whether giving at-risk children daily oral insulin could prevent or delay type 1 diabetes (T1D). Conducted by researchers from Helmholtz Munich and the Technical University of Munich across five European countries, the study enrolled more than 1,000 children with a genetic risk for T1D. Results published in The Lancet show that while oral insulin did not prevent the development of islet autoantibodies—an early sign of diabetes—it was safe and well tolerated. Importantly, researchers found that some children who received oral insulin developed diabetes more slowly than those given a placebo, suggesting potential protective effects in certain genetic subgroups.   Further analysis revealed that the response to treatment depended on the child's insulin gene variant. Children with genetic versions that raise diabetes risk appeared to benefit, showing delayed onset of the disease, while those without the risk variant did not. These findings point toward a future of personalized prevention, where genetic screening could help identify which children might benefit most from oral insulin. Researchers will continue following the participants until age 12 to assess long-term effects. The study marks a major milestone in decades of diabetes prevention research, highlighting both the promise and complexity of developing tailored, early interventions against type 1 diabetes. XX Joint US-Chinese research looking at generating new beta cells from stomach cells. Upon turning on the "genetic switch," the human stomach cells were converted to insulin-secreting cells within the mice and resembled pancreatic beta cells with respect to gene and protein expression. Encouragingly, when those experiments were done with diabetic mice, insulin secreted from the transformed human cells helped control blood sugar levels and ameliorated diabetes. The scientists hope that a similar approach can be taken to convert cells from a patient's own stomach into insulin-secreting cells directly within the body. Importantly, additional studies are needed to address if this approach is safe and effective to be used in patients. https://www.technologynetworks.com/cell-science/news/human-stomach-cells-tweaked-to-make-insulin-406694 XX A new study in Nature Metabolism may help explain why children born to mothers with type 1 diabetes are less likely to develop the disease early in life compared to those whose fathers or siblings have it. Researchers looked at nearly 2,000 mothers and their children and found that  kids whose moms have type 1 diabetes show changes in their DNA that may actually help protect them. These aren't genetic mutations, but epigenetic changes — chemical tags that turn certain genes on or off. The study found these changes in genes tied to the immune system and type 1 diabetes risk, suggesting that a mother's condition during pregnancy can shape her child's immune response in a protective way. Scientists identified more than 500 areas of DNA where these changes occurred, many in regions that control how the body's immune system works. Most of the changes appeared to calm down the kind of overactive immune response that leads to type 1 diabetes. Researchers even created a "methylation score" to help measure this protective effect. They say the next step is to confirm these results in more diverse groups and figure out exactly how these DNA changes help prevent early diabetes. https://www.news-medical.net/news/20251110/Maternal-type-1-diabetes-may-protect-children-from-developing-the-disease.aspx XX A new study from Karolinska Institutet and Stockholm University reveals that sons born to mothers with type 1 diabetes may develop early vascular dysfunction—independently of metabolic health. The finding may help shape future strategies to prevent cardiovascular disease early in life.     Children of women with type 1 diabetes are known to be at increased risk of developing cardiovascular diseases. This new study, published in Cell Reports Medicine, is the first to show that the risk is linked to early dysfunction in blood vessel cells in sons, even before any metabolic issues arise. The team is now investigating the long-term effects of maternal diabetes, with a particular focus on why sons seem to be affected earlier than daughters. https://medicalxpress.com/news/2025-11-sons-mothers-diabetes-early-vascular.html XX A new study presented at Kidney Week 2025 has shown that the drug finn-uh-near-own  a nonsteroidal mineralocorticoid-receptor antagonist, significantly reduced albuminuria—a key marker of kidney damage—in people with type 1 diabetes (T1D) and chronic kidney disease (CKD). This is the first major breakthrough for this population in more than 30 years. Researchers found that patients taking finerenone saw a 25% average reduction in albuminuria compared to placebo, an improvement that suggests a lower long-term risk for dialysis or kidney transplant. The phase 3 FINE-ONE trial involved 242 adults with T1D and CKD, and results showed benefits as early as three months. The drug was generally well tolerated, with side effects similar to those seen in patients with type 2 diabetes, though mild hyperkalemia (high potassium levels) was slightly more common. Experts say the findings could change the way doctors treat kidney complications in type 1 diabetes, an area that hasn't seen new therapies since the early 1990s. Currently, treatment options rely on blood pressure and blood sugar management, along with renin-angiotensin system (RAS) inhibitors. Finerenone, which is already approved for type 2 diabetes-related CKD, targets overactivation of a receptor that drives kidney damage. Based on these results, Bayer plans to seek FDA approval in 2026 for use in people with T1D and CKD. Researchers and clinicians alike are calling the study "groundbreaking," noting that it opens the door to future research on how finerenone might not just slow kidney decline—but possibly prevent it altogether. https://www.medscape.com/viewarticle/finerenone-offers-hope-kidney-disease-type-1-diabetes-2025a1000uzi?form=login   XX This week, Tandem Diabetes Care (Nasdaq:TNDM) announced a major milestone for its Mobi miniature durable insulin pump system. San Diego-based Tandem revealed that it received FDA approval for the Android version of its Mobi mobile app. Clearance brings Mobi — which the company describes as the world's smallest, durable automated insulin delivery system — to more users. The pump, which pairs with Tandem's Control-IQ+ algorithm, previously worked with iOS software.   Tandem — one of the largest diabetes tech companies in the world — expects to begin a limited rollout next month, followed by full commercial availability in early 2026. This marks the latest milestone for the company, which continues to expand its offerings and widen its reach within the diabetes patient population.   We had a great interview with Tandem on our previous episode, but as I said at the time, it was coming before their earnings call. So here's an update: The company plans to submit the tubeless mobi to the fda before the end of this year.. possible approval and shipping date is hoped for by middle of 2026. Trials for their fully closed loop next-generation algorithm which we tlkaed abou ton the show should be launched in 2026 The Sigi patch pump will be developed and launched as a next-generation version of the Mobi Great job by Dr. David ? Ahn – he posted on IG after getting a message from tandem CEO John Sheridan? 1. First, the Tandem X3 *is* still absolutely in development, contrary to my speculation In yesterday's video. As many of you appropriately pointed out, there is definitely a market for a 300 unit pump, a pump with a screen, and a pump that does not require smartphone control. So from our brief chat, the sense I got that is that the X3 would be more of a refresh of the X2 with newer components, such as a USB-C connector and better memory, rather than a total redesign from the ground up. In terms of timing, all I could get was that it was "not too far distant in the future," which could mean anything I guess, but at least it's still on the way! 2. Next up, he also reassured me that they are working closely with Dexcom to support the G7 15 Day sensor within the next few months. I suspected as much, but it's always good to hear confirmation. 3. Lastly, he did confirm that Tandem is far along in developing a Caregiver/Follow app to allow the remote viewing of glucose and insulin data from a Tandem pump. He explained that it will be based on Sugarmate, the popular diabetes data dashboard app that Tandem acquired back in Jun 2020. While I don't know if every feature will make it into the Tandem caregiver app, Sugarmate is well-liked for its highly customizable dashboard and highly configurable alerts. Sugarmate even has the option to send a text message or phone call for urgent lows. Regardless, a true follow/Caregiver app will be welcomed with open arms by all caregivers and Tandem users who use Libre 3 Plus. https://time.com/7318020/worlds-top-healthtech-companies-2025/ XX Senseonics submits Eversense 365 – their year long implantable CGM for a CE mark, European Approval and expect to launch there soon. Eversense will be integrated with the sequel twist pump – again I'm hearing soon but no timeline. Intersting to note that one year inseration was approved in the US just about a year ago, so the first patients will be having their CGMs changed out – for the first time – pretty soon. https://www.drugdeliverybusiness.com/senseonics-q2-2025-sales-beat-ce-mark/ XX A confusing study out of Rutgers - these researcher say  metformin reduces some of the key benefits normally gained from regular physical activity. These include improvements in blood vessel health, physical fitness, and the body's ability to regulate blood sugar. Since 2006, doctors have typically encouraged patients with elevated blood sugar levels to combine metformin with exercise, expecting that the two proven treatments would produce stronger results together. However, the new research suggests this may not be the case. In this study, Exercise alone improved vascular insulin sensitivity, meaning blood vessels responded better to insulin and allowed more blood flow to muscles. This matters because insulin's ability to open blood vessels helps shuttle glucose out of the bloodstream and into tissues, lowering blood sugar after meals. But when metformin was added, the improvements shrank. The drug also diminished gains in aerobic fitness and reduced the positive effects on inflammation and fasting glucose. The findings don't mean people should stop taking metformin or exercising, Malin said. Instead, it raises urgent questions for doctors about how the two treatments can be combined and the need for close monitoring. Malin hopes future research will uncover strategies that preserve the benefits of both. https://scitechdaily.com/popular-diabetes-drug-metformin-may-cancel-out-exercise-benefits-study-warns/ XX XX https://www.medtechdive.com/news/Revvity-Sanofi-diabetes-test-Kihealth-seed-round/802133/   XX Dexcom recalled an Android app for its G6 glucose sensor due to a software problem that could cause the app to terminate unexpectedly. The issue could cause users to miss alarms, alerts or notifications related to estimated glucose values, according to a Food and Drug Administration database entry posted Oct. 30. The glucose sensor and the app are still available, but Dexcom required users to update the app to a new version. Dexcom began the recall on Aug. 28. The FDA designated the event as a Class 1 recall, the most serious kind. Dexcom sent a notification to customers in September about the software bug, which applies to version 1.15 of the G6 Android app. To use the app, customers must update it to a new version, according to the entry. https://www.medtechdive.com/news/dexcom-recall-g6-cgm-app/804630/ XX https://www.medscape.com/viewarticle/automated-insulin-delivery-boosts-glycemic-control-youth-2025a1000ub3 XX Tidepool partners with smart ring maker OURA.. press release says: to support a groundbreaking dataset intended to be broadly available for diabetes research, with participation limited to individuals who opt in through Tidepool.         Tidepool will pair biometric data from Oura Ring – sleep, activity, heart rate, temperature trends, and menstrual cycles – with diabetes device data, including continuous glucose monitors (CGMs) and insulin pumps. The result will provide researchers with an unprecedented dataset to accelerate the development of new clinical guidelines, next-generation diabetes technology, and personalized care models.   Recruitment is expected to launch in early 2026 through an IRB-approved study. By opting in to this study, participants consent to sharing their data with Tidepool's Big Data Donation Project, where data is de-identified and, with participant consent, shared with academics, researchers, and industry innovators to accelerate diabetes research. https://aijourn.com/tidepool-collaborates-with-oura-to-advance-inclusive-diabetes-research-through-wearables/ XX Eli Lilly launches two new clinical trials for baricitinib. These phase 3 trials will investigate whether the drug can delay T1D onset or progression and will open for recruitment soon. Baricitinib has the potential to extend the "honeymoon period" of T1D, meaning that it could preserve remaining insulin-producing beta cells earlier in disease progression. More beta cells mean better blood sugar management—and potentially reduced long-term complications. JAK inhibitors, including baricitinib, are already FDA-approved for other autoimmune diseases, such as rheumatoid arthritis, alopecia, and more. JAK signaling pathways are associated with overactive immune responses, so blocking this pathway may turn down the immune response. The phase 2 Breakthrough T1D-funded BANDIT study was key in showing that this drug is safe and effective in T1D. Importantly, baricitinib is a once-daily oral pill—meaning its use is simple and easy.   https://www.breakthrought1d.org/news-and-updates/two-new-trials-baricitinib-to-delay-t1d/ XX   Insulet is taking diabetes awareness into the workplace. Having found 79% of people with diabetes have faced bias or misunderstanding at work, the medtech giant is rolling out a range of resources intended to trigger changes in how workplaces approach the condition. Lots going on for Diabetes Awareness month.. some notables.. Insulet's "The Day Diabetes Showed up to Work" campaign. based on a survey of almost 10,000 people 79% of people with diabetes have faced bias or misunderstanding at work,.   Almost 90% of people with diabetes surveyed reported experiencing barriers at work due to their condition, and more than 40% of people with diabetes and caregivers said they have workplace-related anxiety tied to the metabolic disease. Around one-quarter of respondents reported fears that diabetes could limit opportunities or lead to workplace discrimination and judgment, and a similar proportion of people said they conceal their condition. https://www.fiercepharma.com/marketing/widespread-workplace-challenges-people-diabetes-spark-insulet-campaign XX New directive issued by the Trump administration could mean people seeking visas to live in the U.S. might be rejected if they have certain medical conditions, including diabetes or obesity.   The guidance, issued in a cable the State Department sent to embassy and consular officials and examined by KFF Health News, directs visa officers to deem applicants ineligible to enter the U.S. for several new reasons, including age or the likelihood they might rely on public benefits.   The guidance says that such people could become a "public charge" — a potential drain on U.S. resources — because of their health issues or age.   The cable's language appears at odds with the Foreign Affairs Manual, the State Department's own handbook, which says that visa officers cannot reject an application based on "what if" scenarios, Wheeler said.   The guidance directs visa officers to develop "their own thoughts about what could lead to some sort of medical emergency or sort of medical costs in the future," he said. "That's troubling because they're not medically trained, they have no experience in this area, and they shouldn't be making projections based on their own personal knowledge or bias."   Immigrants already undergo a medical exam by a physician who's been approved by a U.S. embassy. https://www.npr.org/2025/11/12/nx-s1-5606348/immigrants-visas-health-conditions-trump-guidance XX SAN DIEGO---Nov. 14, 2025—DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of Dexcom's World Diabetes Day campaign. The advocates – ranging from ages six to 68, spanning various types of diabetes, and hailing from four continents and five countries – were selected from 1,000 open call submissions based on their experiences advocating for people with diabetes in their communities. While each person's experience with diabetes is unique, they share a common passion for advocacy – and use of Dexcom's glucose biosensing technology. "Through advocacy, I strive to show others, especially children and newly diagnosed patients, that diabetes is not a limitation but an opportunity to grow stronger, inspire resilience and pursue ambitious goals," said Maria Alejandra Jove Valerio, one of Dexcom's new advocates. "What began as a diagnosis at age seven has grown into a lifelong mission to uplift others." This effort represents the first time Dexcom has sourced voices from the broader diabetes community specifically for its World Diabetes Day campaign, reinforcing Dexcom's history of and commitment to giving real people with diabetes a platform to share their story on a global stage. Through engaging, editorial-style portraits and deeply personal stories, the campaign highlights each advocate's personal experience with diabetes, what misconceptions about diabetes they'd like to dispel and how they want to inspire others with diabetes to discover what they're made of. To prepare for the spotlight, the group of advocates met in Los Angeles for a World Diabetes Day photoshoot which included a surprise visit from Grammy-nominated artist, actor, producer and Dexcom Warrior Lance Bass and author, producer, actress and Stelo*Ambassador Retta. This visit offered the advocates an opportunity to exchange stories and personal perspectives on the meaning of diabetes advocacy and how they live it each day. Behind the lens at the shoot was another member of the diabetes community—photographer Tommy Lundberg who lives with Type 1 diabetes. "Directing this photoshoot was nothing short of inspiring. Each of these advocates has a unique an XX On what would have been the 100th birthday of its visionary founder Alfred E. Mann, MannKind Corporation (Nasdaq: MNKD), in partnership with Alfred E. Mann Charities and The Diabetes Link, announced the launch of the Centennial Al Mann Scholarship. The new program will distribute $100,000 in scholarship funds to support at least 10 young adult students living with diabetes as they pursue higher education in life sciences.   Launched in Diabetes Awareness Month, the scholarship program honors Alfred E. Mann's enduring legacy of innovation, philanthropy, and his lifelong commitment to improving the quality of human life through medical advancement. Deeply passionate about giving back, Mr. Mann believed that his success should continue to serve humanity long after his passing, a belief that lives on through this initiative.   Each scholarship recipient will be awarded up to $10,000, distributed in annual installments of $2,500 throughout the course of their studies. Depending on the length of their degree program, recipients may receive between two and four installments (up to the full $10,000 per student). The first awards will be made for the 2026 academic year.   "Al Mann dedicated his life to helping people with serious medical conditions live longer, healthier lives. This scholarship is a reflection of that spirit," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "By supporting students living with diabetes who are pursuing careers in the life sciences and adjacent fields, we're honoring Al's legacy and investing in the future of innovation and care. This program is about giving back to the community we serve and empowering the next generation to carry forward Al's mission of making a meaningful difference in people's lives."   Alfred E. Mann Charities and MannKind will partner with The Diabetes Link to launch the program to serve young adults (aged 18-22) living with either type 1 or type 2 diabetes with their higher education goals. Those eligible will include incoming freshmen and current students pursuing 2- or 4-year degrees. The application window will open in early 2026, and for those interested in receiving notifications, an early interest form is available. More information about the scholarship will be shared on thediabeteslink.org.   "We're honored to partner with MannKind to expand access to higher education for young adults with diabetes," said Manuel Hernández, Chief Executive Officer of The Diabetes Link. "At a time when the cost of college continues to rise, this scholarship helps ease the financial burden and carries forward the spirit of Al Mann, whose vision and legacy continue to inspire us."   Mr. Mann was MannKind's Chairman of the Board from 2001 until his passing in February 2016 and served as Chief Executive Officer from November 2003 until January 2015. Driven by a desire to improve lives and fill unmet medical needs, for more than six decades he founded 17 companies and developed breakthrough medical devices, including insulin pumps, cochlear implants, cardiac pacemakers and retinal prostheses. In 1997, Mr. Mann saw the potential of a dry powder insulin formulation to change the way diabetes is treated and invested nearly $1 billion to help bring Afrezza® (insulin human) Inhalation Powder to market.   About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.   With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.   Learn more at mannkindcorp.com.   About Alfred E. Mann Charities, Inc. Alfred E. Mann Charities, Inc. became active in 2016, following the passing of the organization's benefactor, Alfred E. Mann. Throughout his life, Al was passionate about philanthropy and was dedicated to prolonging and improving the quality of human lives through innovation in the fields of healthcare and the use of medical devices. It was important to Al that his success and assets continue to better human lives even after his own passing.   Alfred E. Mann Charities, Inc. (formerly known as Alfred E. Mann Family Foundation) has similarly placed its primary focus on healthcare and medical innovation, as our organization believes this is where we can have the greatest impact on humanity and human health throughout the world. Alfred E. Mann Charities, Inc. is also dedicated to promoting arts, culture, education, and community development across Los Angeles and throughout the world in order to best serve people and this planet.   Learn more at aemanncharities.org.   About The Diabetes Link The Diabetes Link is the only national nonprofit organization dedicated to empowering young adults living with diabetes. Founded by and for young adults, The Link serves this community through peer support, leadership opportunities, and practical, evidence-based resources designed for real life. Its network of campus and community chapters, active online community, and robust Resource Hub help young adults navigate the transitions of early adulthood while managing diabetes. The organization envisions a future where every young adult living with diabetes has

Sara Hägg, PhD is an associate professor at Karolinska Institutet, where she leads the Molecular Epidemiology of Aging Group. Her work focuses on human biomarkers of aging - especially biological age “clocks” built from epigenetic, proteomic, and metabolomic data - and on turning Nordic registry resources into clinically useful aging measures.In this episode:* What biological/epigenetic age clocks actually measure (and what they don't)* Accuracy, error bars, and why clocks aren't clinic-ready yet* Epigenetic vs. proteomic vs. metabolomic clocks - strengths and trade-offs* Organ-specific clocks (liver, ovary, kidney) and what they reveal* Why uncertainty spikes at life transitions; menopause as a natural “stress test”* PC (principal-component) clocks and noise reduction* Nordic registry & Swedish Twin Registry advantages; UK Biobank use* Direct-to-consumer tests: interpreting results and common pitfalls* AI's role in building/validating clocks and handling uncertainty* What would move the field fastest (data, standards, trials) and where Sweden standsShow notes for this episode will be available after this airs. Sign up for the LEVITY newsletter to get them straight to your inbox: reachlevity.comLEVITY is co-hosted by Patrick Linden, philosopher and author, and Peter Ottsjö, journalist and author.CHAPTERS00:00 Introduction03:27 Why Sweden lags behind in longevity science08:04 Nordic registry & Swedish twin registry advantages; UK Biobank use10:05 What is biological age?16:33 The rise of epigenetic clocks24:22 The importance of aging clocks32:04 Beyond methylation: proteomic and metabolomic clocks35:12 Organ clocks39:37 Do aging clocks generalize?54:37 The cost of aging clocks01:03:18 Uncertainty and AI01:17:10 Solving aging - where do we stand?01:28:10 Book recommendations Hosted on Acast. See acast.com/privacy for more information.

Visste du att ditt nervsystem kan spela en nyckelroll i att dämpa inflammation? I det här avsnittet pratar vi om vagusnerven – kroppens längsta kranialnerv – och hur den fungerar som en bro mellan hjärnan och immunförsvaret. Forskning visar att aktivering av vagusnerven kan påverka inflammatoriska sjukdomar som reumatism – till och med utan läkemedel.Vi utgår från banbrytande forskning av professor Peder Olofsson på Karolinska Institutet, som visar att elektrisk stimulering av vagusnerven kan sätta igång kroppens egna mekanismer för att stänga av inflammation. Men vi pratar också om enkla och naturliga sätt att själv påverka vagustonus – till exempel genom andning, kallt vatten, röstövningar och rörelse.

New research from the Karolinska Institutet in Sweden shows that your brain interprets certain aromas as taste, activating the same regions as sugar Retronasal smell — odor molecules rising from your mouth during eating — creates flavor, while orthonasal smell (sniffing) detects outside odors Functional MRI scans revealed that the insula, the brain's taste cortex, responds to sweet-associated aromas like vanilla or strawberry as if sugar were present Everyday experiences, such as food tasting bland during a cold, highlight the difference between taste vs. flavor and the role of retronasal airflow Sweet-linked aromas can help reduce added sugar in foods by enhancing perceived sweetness, though they do not change calorie or glucose content

Sjukdomsutbrott, naturkatastrofer och krig är exempel på situationer där behovet av vård snabbt överstiger tillgängliga resurser. Vilka är de största skillnaderna mellan att jobba på ett sjukhus i Sverige och ett fältsjukhus i Gaza och varför stämplas läkare som uttalar sig efter att ha jobbat i krig som politiska aktivister? På det svarar Märit Halmin, narkos- och intensivvårdsläkare på Södersjukhuset i Stockholm samt verksam på Centrum för hälsokriser vid Karolinska Institutet. Märit har även jobbat för Läkare utan gränser i många delar av världen, senast på ett fältsjukhus i Gaza. Dessutom funderar Emma och Clara på det svåra med triage och hur expert- och aktivistrollen kan kombineras.Klipp och musik:Albéniz (arr. Naughtin) - Suite Española No. 1 V. Asturias - LeyendaLivet i Mattelandet - Allting går att sorteraTV4 Nyhetsmorgon, Läkaren om Gaza- ”Kalla det vad ni vill – men helvetet måste ta slut”P4 Extra Gästen - Läkaren Märit Halmin jobbar i Gaza- Vem som helst kan dö när som helstVår A-kurs i katastrofmedicin hittar du på instagram, @akursen_poddmail: akursenpodd@gmail.com Hosted on Acast. See acast.com/privacy for more information.

Vad betyder det att Bari Weiss går till CBS? Och så tjafsar vi med Aftonbladet Plus om deras hårdvinklade nudeljournalistik. Lyssna på alla avsnitt i Sveriges Radio Play. Bakom kulisserna på bevakningen om hemkomna PalestinaaktivisterI början av veckan kom Greta Thunberg och flera andra aktivister slutligen hem till Sverige, efter en lång seglats mot Gaza och flera dagar i israeliskt fängelse. Redan på Arlanda var flera journalister på plats för att få svar på en central fråga: Hur illa behandlad blev Greta Thunberg i det israeliska ökenfängelset Ketziot? I ankomsthallen fick de inga svar utan hänvisades till en improviserad presskonferens på Sergels torg några timmar senare, omgivna av demonstranter. På plats var stämningen minst sagt märklig. Erik Petersson har träffat Ekots Mattias Pleijel och TV4:s Lisa Svensson.Varför rekryterar etablerade CBS News den etablissemangskritiska Bari Weiss?I veckan blev det klart att Bari Weiss, som för några år sedan lämnade sin roll som redaktör och opinionsjournalist på The New York Times med buller och bång, nu tar över som chefredaktör för en av USA:s största nyhetsredaktioner. Dessutom köper CBS moderbolag Paramount uppstickarsajten The Free Press som Weiss grundade i protest mot den wokekultur hon menade rådde i etablerade medier.Joanna Korbutiak ringde upp Expressens före detta chefredaktör Thomas Mattsson, numera bland annat senior advisor på Bonnier News, för en analys.Hårdvinklad nudeljournalistik”NY STUDIE: Risk att dö i förtid av populära rätten”, så löd rubriken till den låsta artikeln på Aftonbladets sajt, men stämmer det verkligen?Freddi Ramel fortsätter sitt korståg mot Aftonbladet Plus hälsojournalistik och intervjuar deras chef Helena Utter och Ingrid Larsson, näringsfysiolog på Karolinska Institutet.

In our first episode of the XXplored Women's Brain Health podcast, our resident expert and host Dr Laura Stankeviciute from University of Gothenburg engages with leading neuroscientists Professor Liisa Galea from University of Toronto and Dr Maria Teresa Ferretti from Karolinska Institutet to explore the critical intersection of sex, gender, and brain health. Together our guests discuss their personal journeys into neuroscience, the biological differences in brain health, the impact of hormonal changes, and the vulnerability of women to Alzheimer's disease. The conversation also addresses the barriers to inclusion in clinical research, the implications of neurosexism, and the importance of precision medicine. The episode emphasises the need for early diagnosis and the societal stigma surrounding women's health issues, while advocating for a more inclusive and evidence-based approach to brain health research and treatment. This first show sets the scene for what will be an ongoing series of shows, delivered within the Dementia Researcher podcast. Takeaways ● Sex differences shape the brain at every level – structure, hormones, immunity, and function. ● Menopause is a key vulnerability window for women's brain ageing and Alzheimer's risk. ● Women face higher Alzheimer's prevalence, not just because they live longer. ● Women were excluded from trials for decades, leaving dangerous gaps in knowledge. ● Fear of neurosexism and misunderstandings of feminism slowed progress. ● Precision medicine must include sex and gender or risk missing early diagnoses. ● Research funding and clinical guidelines lag far behind need. ● Momentum is building: younger researchers and public interest are pushing change. ● Core message: Different ≠ inferior. Diversity drives discovery. -- Find more information on our guests, and a full transcript of this podcast on our website at: https://www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of University College London, Dementia Researcher or its funders. -- Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://www.bsky.app/profile/dementiare…archer.bsky.social -- Download and Register with our Community App: https://www.onelink.to/dementiaresearcher

In this episode of the Me&My Health Up podcast, Anthony Hartcher interviews Cameron Borg, a leader in the nutrition space. Cameron shares his personal journey through various diets, including veganism, and how it led him to understand the importance of local and seasonal eating, outdoor living, and the impact of light exposure on health. They discuss practical tips for building healthy meals, the significance of meal timing, and the role of protein in nutrition. Cameron emphasises the importance of enjoying food and maintaining a healthy mindset around eating, while also providing insights on how to adapt to different environments and food availability.TakeawaysCameron's journey through veganism led to a deeper understanding of nutrition.Local and seasonal eating is crucial for health.Outdoor living and light exposure significantly impact well-being.Meal timing, especially breakfast, is important for health.Protein prioritisation is key in meal planning.Enjoying food with others enhances its benefits.Don't stress about occasional deviations in diet.The body has a remarkable ability to adapt to different diets.Nutrition is complex and not just about macros.A healthy mindset around food is essential for overall well-being.About Cameron Borg Cameron Borg is a nutritionist, podcaster, and science writer passionate about helping people rediscover balance and vitality. Through The Ricci Flow Nutrition Podcast and his Substack, he explores the intersection of science, philosophy, and health — from nutrition and light exposure to mindset and environment. Based in Sweden, Cameron continues his work as an educator and practitioner while studying at the Karolinska Institutet, sharing insights that empower others to reconnect with nature and the true foundations of wellbeing.  Connect with Cameron Borg: Substack: https://ricciflow.substack.com/ Website: https://www.ricciflownutrition.com/ YouTube: https://www.youtube.com/@RicciFlowNutrition Instagram: https://www.instagram.com/ricciflownutrition/ Twitter/X: https://x.com/ricciflowhealth LinkedIn: https://www.linkedin.com/in/cameron-borg/ Don't forget to like, comment, and follow for more health tips and wellness.   YouTube: / ⁠⁠⁠https://www.youtube.com/@memywellness⁠⁠⁠  Instagram:   / ⁠⁠⁠⁠https://www.instagram.com/meandmywellness/⁠⁠⁠⁠   Facebook:    / ⁠⁠⁠⁠https://www.facebook.com/meandmywellness.com.au⁠⁠⁠⁠      X (Twitter):   / ⁠⁠⁠⁠https://twitter.com/meandmywellness⁠⁠⁠⁠  LinkedIn:    / ⁠⁠⁠⁠https://www.linkedin.com/company/me&my-wellness/⁠⁠⁠⁠     About me&my health up & Anthony Hartcher:    me&my health up seeks to enhance and enlighten the well-being of others. Host Anthony Hartcher is the CEO of me&my wellness which provides holistic health solutions using food as medicine, combined with a holistic, balanced, lifestyle approach. Anthony holds three bachelor's degrees in Complementary Medicine; Nutrition and Dietetic Medicine; and Chemical Engineering.  Chapters00:00 Introduction to Nutrition Insights03:53 Cameron's Nutritional Journey06:35 The Importance of Local and Seasonal Eating08:52 Outdoor Living and Light Exposure11:28 Building Healthy Meals13:52 Meal Timing and Intermittent Fasting16:34 Understanding Macros and Protein Prioritization18:52 Mindset Around Food and Enjoyment21:32 Connecting with Cameron and Closing Thoughts

Alla har väl hört talas om placeboeffekten, men vad är det och hur funkar det? Det finns även något som kallas för ÖPPEN PLACEBO, där patienten vet om att de får en placebobehandling. Funkar det lika bra? För att få svar på dessa frågor samtalar jag med Fredrik Borg, doktorand vid avdelningen för fysioterapi, Karolinska Institutet, och leg kiropraktor och lärare på Skandinaviska Kiropraktorhögskolan och Anna Pettersson, Medicine Doktor och assisterande lektor på Karolinska Institutet.

Mia Skäringer delar med sig om sin egen nervositet inför liveframträdanden, medan Jenny Jägerfeld berättar om när hon fick springa ut och kräkas inför 500 åhörare, och funderar över varför mindre prestationer ibland känns mer skrämmande än de riktigt stora. Varför blir vi nervösa – och kan den där snudd på outhärdliga känslan faktiskt hjälpa oss att prestera bättre? Erik Andersson, forskare i klinisk psykologi vid Karolinska Institutet, reder ut om nervositet kan tränas bort. Vi får också veta att nervositet till viss del är ärftligt.

Erica får sin första tvångstanke när hon är 12 år gammal och hennes mamma drabbas av cancer. Tänk om jag vill att mamma dör, tänker Erica. Lyssna på alla avsnitt i Sveriges Radio Play. Tanken har ingen förankring i verkligheten men går inte att få bort. Tanken skapar mycket ångest och blir början på många år av jobbiga tankar. Till slut biktar hon sig och berättar det här för sin mamma. Veckans program tar itu med olika typer av jobbiga tankar som inte vill släppa taget. Det är katastroftankar, ältande, tvångstankar och tankar som ställer sig i vägen när du till exempel ska prestera något. Det finns sätt att stoppa tankar på, eller i varje fall få dem att blekna och ta mindre plats i ditt huvud. Medverkande: Linda Jüris, psykolog, Camilla Sköld, forskar och utbildar om Mindfullness vid Karolinska Institutet, Johan Plate, idrottspsykologisk rådgivare, Marie Banich, professor i kognitiv neurovetenskap på University of Colorado at Boulder.Programledare: Ulrika Hjalmarson NeidemanProducent: Stina NäslundReporter: Olivia Sandell

Resan mot Nordpolen 1897 borde inte ha slutat med katastrof menar Bea Uusma, som under 30 år använt en mängd vetenskapliga metoder för att förstå varför de tre männen dog. Lyssna på alla avsnitt i Sveriges Radio Play. Modern dna-teknik på blodfläckar, korrosionsstudier över Andrées gevär och avancerade genomlysningsmetoder på hans mögliga dagbok är exempel på vad Bea Uusma använt för att lösa mysteriet, som också fick henne att utbilda sig till läkare. Nu vill hon hitta nya skelettdelar vid katastrofplatsen på Vitön att analysera forensiskt, men klimatförändringarna gör att det brådskar - snart finns kanske inget kvar där. En annan dramatisk polarexpedition var den Otto Nordenskjöld gjorde till Antarktis. Historikern Dag Avango berättar om hur mycket gick fel trots att Nordenskjöld var bättre förberedd. Avango själv har varit nära att förolyckas vid en egen tur till Arktis, men ändå reser han tillbaka till polartrakterna, för att studera expeditionernas lämningar som kulturarv. Medverkande: Bea Uusma, läkare, författare och forskningsanknuten till medicinens historia och kulturarv vid Karolinska Institutet; Dag Avango, professor i historia vid Luleå tekniska universitet. Poddledare: Lena Nordlundlena.nordlund@sr.seProducent: Björn Gunérbjorn.guner@sr.se

I måndags kom A-kursen i biologiskt åldrande och nu har det blivit dags för överkursen, det vill säga hela Emmas intervju med Sara Hägg som är docent i molekylär epidemiologi och som forskar på just åldrande vid Karolinska Institutet. Sara berättar bland annat om vad zombieceller är för något, om kalorirestriktion ett bra sätt att bromsa sitt åldrande på och om det finns djur som inte åldrasFölj oss på instagram @akursen_poddmail: akursenpodd@gmail.com Hosted on Acast. See acast.com/privacy for more information.

Många drömmer om evig ungdom och biologisk ålder har blivit något som man kan mäta och försöka bromsa in. Men hur gör man för att åldras på ett hälsosamt sätt och är den första 200-åringen redan född? Det svarar Sara Hägg på som är docent i molekylär epidemiologi och som forskar på just åldrande vid Karolinska Institutet. Dessutom pratar Emma och Clara om när Kardashiansystrarna lät testa sin biologiska ålder, om ålderssprången som påstås infinna sig vid 44 och 60 års ålder och om man kan hålla sig ung bara man går riktigt snabbt.Klipp och musik:Alphaville - Forever Young InstrumentalAlphaville - Big in JapanSR P4 Göteborg, Nu kan vår inre ålder mätasNyhetsmorgon, Dr Mikael "Så förändras kroppen när vi åldras”Nyhetsmorgon, Kroppen åldras mest vid 44 och 60 år – ”Du ser absurt ung ut”The KardashiansAvsnittet är en repris från oktober 2024.mail: akursenpodd@gmail.com Hosted on Acast. See acast.com/privacy for more information.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit japanpodden.substack.com

Karolinska Institutet och University of Tokyo samarbetar inom området Life Sciences och det handlar i korthet om att identifiera skador på cellernas kromosomer - forskningen tyder på att kromosomskador ofta uppträder i samband med nya cancertumörer. Japanpodden besökte nyligen Karolinska Institutet och fick en rundvandring i lokalerna och en chans att sitta ned med projektets två eldsjälar - Katsuhiko Shirahige från University of Tokyo och Camilla Björkegren på KI. NYHETERTokyo upplever rekordlång värmeböljaTokyo upplever just nu den längsta värmeböljan i stadens historia. I tio dagar i rad har temperaturen legat över 35 grader. Sjukvården rapporterar kraftigt ökade fall av värmeslag och uttorkning. Myndigheterna uppmanar invånarna att undvika att vistas utomhus mitt på dagen. Forskare varnar för att extremvärmen är ett direkt resultat av klimatförändringar. Samtidigt pressas elnätet hårt av en rekordhög efterfrågan på luftkonditionering. Frågan väcker oro för hur Tokyo ska hantera framtida värmeböljor och hur elnätet ska stå emot trycket.Klartecken för återstartad kärnkraft i FukuokaFukuokas rätt har gett klartecken för fortsatt drift av reaktor 1 och 2 vid Sendai kärnkraftverk, som återfinns i Kagoshima län. Motståndare hänvisar till riskerna med kärnkraft och har pekat på effekterna av katastrofen i Fukushima 2011. Domstolen menar dock att säkerhetsåtgärderna nu uppfyller kraven. Beslutet är en viktig framgång för regeringen, som vill öka kärnkraftens andel i energimixen, från nuvarande ungefär en tiondel till en tredjedel. Mitsubishi skrotar planer på havsbaserade vindkraftsparkerMitsubishi Corporation meddelar att man skrinlägger tre planerade havsbaserade vindkraftsparker. Projekten, belägna i Akita och Chiba, skulle stå klara mellan 2028 och 2030. Men de skenande kostnaderna för utrustning, bränsle och transporter gör dem olönsamma, enligt Mitsubishis egna beräkningar. Höga räntor och den globala energikrisen har förvärrat situationen ytterligare. Japan riskerar därmed att missa målet om 10 gigawatt vindkraft till 2030. Mitsubishi har redan redovisat miljardförluster kopplade till satsningarna. Beslutet betraktas som ett bakslag för Japans gröna omställning.Åklagare gör husrannsakan mot oppositionspolitikerI Tokyo har åklagare genomfört en omfattande husrannsakan mot oppositionspolitikern Akira Ishii som tillhör Nippon Ishin no Kai–partiet (Japan Innovation Party)Ishii misstänks för ha tagit ut statliga medel för en sekreterare som aldrig arbetat för honom.Razzian genomfördes både i partiets huvudkontor och Ishiis egna arbetsrum Ishii själv förnekar brott och beskriver anklagelserna som politiskt motiverade. Fallet väcker frågor om korruption och ansvar i den japanska oppositionen och bedömare räknar med att ett åtal kan komma att komma under hösten, ett åtal som isåfall riskerar att skada förtroendet för hela oppositionsblocket.Kritik mot afrikanska vänortssatsningarEn satsning på vänortssamarbeten mellan japanska städer och afrikanska länder möts av motstånd. Rykten på sociala medier har felaktigt påstått att projekten innebär massinvandring. Det har lett till stadshus runt om i landet blivit nedringda. Bakom initiativet står biståndsmyndigheten JICA Japan International Cooperation Agency, som vill stärka handel och kulturutbyte. Myndigheten betonar att programmet inte har någon koppling till migration. Trots det har främlingsfientliga uttalanden fått stort genomslag. Kommuner efterlyser nu tydligare information för att bemöta desinformationen.Tokyos stad släpper AI-genererad film som visar hur huvudstaden kan drabbas vid ett utbrott från vulkanen Fuji.Askan väntas nå Tokyo inom en till två timmar och kan bli upp till tio centimeter tjock. Transporter på mark och i luften riskerar att stoppas helt, medan el- och telenäten hotas av blöt aska. Invånare uppmanas att lagra mat för tre dagar samt använda masker och skyddsglasögon. Syftet är att öka beredskapen inför ett utbrott som kan inträffa när som helst. Filmen som är tre minuter lång kan ses på Youtube . This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit japanpodden.substack.com

In this episode, Dr Tsen Vei Lim talks to Dr Danilo Romero, a licensed clinical psychologist at the Stockholm Centre for Dependency Disorders in Sweden. The interview covers his research report on the questionable generalisability of the Alcohol Use Disorders Identification Test – Consumption (AUDIT-C) when used as an outcome measure in clinical trials than as a primary care screening tool, highlighting the need for researchers and clinicians to reconsider their application of the AUDIT-C. · What is the AUDIT-C and why it is widely used in primary care and research? [01:13]· What made the authors question the generalisability of the AUDIT-C in clinical trials? [02:02]· The risks of using the AUDIT-C in clinical settings [03:03]· The reason for the ‘ceiling effect' of the AUDIT-C [04:21]· How the authors tested whether the AUDIT-C is useful in measuring treatment progress [05:15]· The key findings of the study [06:06]· What ‘collider bias' is and how it could manifest in studies that use the AUDIT-C [06:59]· What the findings mean for studies that have used AUDIT-C in the past [09:23]· How the findings contribute to policy or practice [10:30]· Whether the authors, as clinical psychologists, personally use the AUDIT-C [11:28]· Birds eye view of psychiatric screening measures [12:40]About Tsen Vei Lim: Tsen Vei is an academic fellow supported by the Society for the Study of Addiction, currently based at the Department of Psychiatry at the University of Cambridge. His research integrates computational modelling, experimental psychology, and neuroimaging to understand the neuropsychological basis of addictive behaviours. He holds a PhD in Psychiatry from the University of Cambridge (UK) and a BSc in Psychology from the University of Bath (UK). About Danilo Romero: Dr Romero, PhD, is a licensed clinical psychologist at the Stockholm Centre for Dependency Disorders in Sweden. He recently completed his doctorate at Karolinska Institutet, conducting a multimethod project to improve treatment engagement for substance use disorders after acute-care episodes. More broadly, his research covers digital psychiatry, mental health informatics, psychometrics, and novel psychological interventions for substance use disorders.The authors have no conflicts of interest to disclose. Original article: Questionable generalizability of Alcohol Use Disorders Identification Test-Consumption scoring warrants caution when used for outcome monitoring: Evidence from simulated and real-world trial data - https://doi.org/10.1111/add.70074The opinions expressed in this podcast reflect the views of the host and interviewees and do not necessarily represent the opinions or official positions of the SSA or Addiction journal.The SSA does not endorse or guarantee the accuracy of the information in external sources or links and accepts no responsibility or liability for any consequences arising from the use of such information. Hosted on Acast. See acast.com/privacy for more information.

This special episode was recorded at the mid-year symposium of the International Society of Pharmacovigilance (ISoP), 14–15 May 2025. Held in Uppsala, Sweden, the theme of the symposium was Improving information capture for safer use of medicines. The episode is an abridged recording of the concluding fireside chat, where Angela Caro Rojas (president of ISoP), Linda Härmark (director of the Drug Safety Research Unit in the UK), Ghita Benabdallah (national pharmacovigilance centre of Morocco, member of the IsoP advisory board), and Daniele Sartori (senior pharmacovigilance researcher at Uppsala Monitoring Centre), discuss patient engagement in pharmacovigilance.The symposium was a collaboration between ISoP and UMC. Want to know more?Visit the official website of the 2025 ISoP Mid-Year Symposium to learn more about its sessions, speakers and chairs. Not patient but im-patient – read about Sara Riggare's research on patient engagement and other topics.Listen to Henry Zakumumpa talk about his study on adverse event reporting quality in Uganda in this 2025 episode of Drug Safety Matters.Read about the PhD project of Tommy Emil Dzus, Improving causality assessment in pharmacovigilance for safe and sustainable use of medicines in health emergencies, at Oslo Metropolitan University, Norway.Sabine Koch is Head of the Department of Learning, Informatics, Management and Ethics (LIME), at Karolinska Institutet, Stockholm.Details on Mikael Hoffman's research can be found on his profile page on ResearchGate.Take a look at what's in store for participants at the 24th Annual Meeting of ISoP in Cairo, on October 24–27, 2025.Visit the websites of the Drug Safety Research Unit (DSRU), ISoP, Centre Anti Poison et Pharmacovigilance du Maroc, and Uppsala Monitoring Centre, to find out more about their work. Join the conversation on social mediaFollow us on Facebook, LinkedIn, X, or Bluesky and share your thoughts about the show with the hashtag #DrugSafetyMatters.Got a story to share?We're always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!About UMCRead more about Uppsala Monitoring Centre and how we work to advance medicines safety.

Mitt i livet får Tarja Samuelson inte längre ihop bokföringen för familjeföretaget. Sakta började hon förstå att något inte stämmer. Trots att hon bara är 54 år får hon träffa en geriatriker som efter minnestest, hjärnröntgen och biomarkörer i ryggmärgsvätskan konstaterade kognitiv svikt som tyder på alzheimer. Chocken efter diagnosen var total då men nu, sex månader senare, ser Tarja annorlunda på saken. Live har tagit en annan vändning. Medverkar gör också forskare och docent Sofia Schedin Weiss, Karolinska Institutet, vars studier handlar om just framtidens diagnostik. Vad innebär det att få en diagnos idag och hur kommer det se ut framåt? Varför får så många en felaktig kognitiv diagnos idag och vad finns det för risker att ta hänsyn till i och med utvecklad diagnostik? Och varför det är viktigt med en tidig diagnos. Intervjuar gör Johanna Hinteregger, själv anhörig. Det här poddavsnittet görs med finansiella medel från biopharmabolagen Bioarctic och Eisai.

Dr. Cynthia Bulik is a clinical psychologist and one of the world's leading experts on eating disorders. She is the Founding Director of the University of North Carolina Center of Excellence for Eating Disorders and also the founder director of the Centre for Eating Disorders Innovation at Karolinska Institutet in Stockholm, Sweden. Dr. Bulik is Distinguished Professor of Eating Disorders in the Department of Psychiatry at UNC, Professor of Nutrition in the Gillings School of Global Public Health, and Professor of Medical Epidemiology and Biostatistics at Karolinska Institute.  Dr Bulik has received numerous awards for her pioneering work, including Lifetime Achievement Awards from the National Eating Disorders Association, the Academy for Eating Disorders, and the International Society of Psychiatric Genetics. She has written over 750 scientific papers, and several books aimed at educating the public about eating disorders.  Currently, Dr. Bulik's focus  is in the reconceptualization of eating disorders as being a metabo-psychiatric diseases. Food Junkies is keen to explore this interest in how metabolic disease plays a role in disordered eating: can this construct be the  common ground to start to understand the muddy waters  between eating disorders and food addiction?  In This Episode, You'll Learn:

Semaglutid har gjort sensation som medel mot övervikt. Nu hoppas forskare att det också ska kunna fungera mot allt från hjärtproblem till alzheimer. Lyssna på alla avsnitt i Sveriges Radio Play. Programmet sändes första gången 20240625.Hormonet semaglutid har startat en kapplöpning bland läkemedelsföretagen. Idag säljs det under flera olika varumärken som ett effektivt medel mot diabetes typ 2, och framför allt mot övervikt. Men nu upptäcker man att det har allt fler effekter. I studier ser man positiva resultat mot hjärt- och kärlsjukdomar och mot njurproblem.Det finns också förhoppningar om att semaglutid och närbesläktade substanser ska kunna fungera som ett slags bromsmedicin för patienter med Parkinsons och Alzheimers sjukdomar. Just nu pågår en internationell studie på alzheimerpatienter med deltagare på Karolinska Institutet i Huddinge. Men frågan är vad vi vet om de här relativt nya ämnenas biverkningar och långtidseffekter och inte minst vad de kommer att kosta sjukvården. Idag är det endast diabetiker, framför allt med typ 2, som får ämnet subventionerat. Är semaglutid och liknande hormoner på väg att bli vårt vanligaste läkemedel? Medverkande: Hindrik Mulder, professor i ämnesomsättning Lunds universitet; Kerstin Brismar, läkare och diabetesforskare Karolinska institutet Solna, Mikael Rydén; professor och diabetesforskare Karolinska institutet Huddinge; Jenny Vinglid, generalsekreterare Obesitas Sverige; Ylva Trolle Lagerros, docent och forskare Centrum för Obesitas Stockholm; Anne Börjesson Hanson, alzheimerforskare Karolinska institutet.Reporter: Tomas LindbladProducent: Björn Gunérbjorn.guner@sr.se

Peter gillar mat, dryck och god samvaro. Men en dag får han veta att han är dödligt sjuk. Hans lever har slutat fungera. Lyssna på alla avsnitt i Sveriges Radio Play. Peter Jonson har ett socialt arbete med mycket representation. Det är goda middagar och många drinkar. Han tycker om att njuta av mat och dryck och att vara social. Människor runt honom frågar om han har varit utomlands, han ser solbränd ut i ansiktet. Det han inte anar är att hans lever håller på att lägga av, att han är dödligt sjuk och akut behöver en ny lever. Levern är ett stort och viktigt organ. När den mår dåligt märks det oftast inte förrän det gått mycket långt och levern är på väg att sluta fungera. - Vi försöker hitta de här personerna tidigare så att vi kan bromsa och kanske till och med vända sjukdomen, säger läkaren Hannes Hagström.Medverkande: Hannes Hagström, professor och överläkare vid Karolinska universitetssjukhuset, Emilia Hagman, nutritionist och docent i epidemiologi vid Karolinska Institutet, Christina Villard, transplantationskirurg på Karolinska universitetssjukhuset.Programledare: Ulrika Hjalmarson NeidemanReporter: Ninos ChamounProducent: Stina Näslund

Sjukvården kan förbättras om man låter läkarna och patienterna hamna i centrum, med läkaretiken som central komponent. Idag är den rejält försvagad, om den inte rentav har avskaffats, skriver Johan Frostegård, professor i medicin vid Karolinska Institutet. Inläsare: Magnus Thorén

En kvinna låter sin hund bajsa i affären. Arbetskamrater går på lunch utan att fråga en medarbetare. Ohövlighet hör till vardagen på många platser. Lyssna på alla avsnitt i Sveriges Radio Play. Dagens Kropp & Själ utforskar ohövligheten i vårt samhälle. Stressforskaren Dan Hasson menar att vi blivit mindre hövliga mot varandra, och mer lättkränkta. Men det positiva är att mönstret visat sig lätt att vända. För försäljaren Christine är hövlighet ett vackert ord, men också en självklarhet. I arbetet träffar hon många människor. Hon har alltid haft serviceyrken och tycker det är viktigt att se varje människa för den den är oavsett bakgrund. Om någon är otrevlig eller bråkig går hon fram och frågar hur det är, vänligt men bestämt. Medverkande: Dan Hasson, stressforskare vid Karolinska Institutet, Magnus Söderlund, professor som forskar om kundbeteenden i handeln, Sofia Larsson, vett- och etikettexpert, Christine Strand, försäljare.

Preparatet THX kan ha injicerats i upp till 150 000 människor under perioden 1952 till 1989, utan att någon nytta någonsin bevisades i vetenskapliga experiment. Människor som lämnats utan hopp av en bristfällig cancervård vallfärdade till veterinären Elis Sandberg (1910–1989) i Aneby för att få THX, som framställdes av kalvbräss.Den karismatiske och empatiske Elis Sandberg blev en följetong i kvällspress och veckopress under årtionden. Slutet för THX kom först efter att det godkändes som naturläkemedel 1987 och kontroverserna upphörde.I detta avsnitt av podden Historia Nu samtalar programledaren Urban Lindstedt med Maria Josephson, idéhistoriker vid Karolinska Institutet, som är aktuell med boken Lex THX – Historien om Sveriges största medicinska konflikt och den märkvärdiga veterinär som skapade den.Om vi förflyttar oss till 1950-talet var sjukvården underdimensionerad och behandlingsformerna mot cancer begränsade. Dessutom saknade många läkare kunskap för att hantera människors oro. Många cancerpatienter skickades helt enkelt hem för att dö – utan smärtlindring. Detta samtidigt som cancerdiagnoserna ökade i samhället.Det var denna lucka som Elis Sandberg fyllde med sitt preparat THX, som han var helt övertygad om kunde bota cancer och en rad andra sjukdomar. Många läkare var intresserade av THX när de saknade fungerande behandlingar för dödssjuka patienter. Samtidigt medverkade Elis Sandberg aldrig fullt ut för att få sitt preparat vetenskapligt bekräftat.Bild: Veterinär Elis Sandberg 1 januari 1966. Wikipedia, Public Domain. Musik Classical Crossover, MoodMode, Storyblocks Audio. Lyssna också på När syfilis spred skam, galenskap och död över Europa. Vill du stödja podden och samtidigt höra ännu mer av Historia Nu? Gå med i vårt gille genom att klicka här: https://plus.acast.com/s/historianu-med-urban-lindstedt. Hosted on Acast. See acast.com/privacy for more information.

Could the very thing we've been told protects our teeth be harming our children's brains?

Julia får fart med diskborsten. Sara ringer ett viktigt samtal. Uppgifter som känns övermäktiga blir gjorda när en annan person är närvarande. Lyssna på alla avsnitt i Sveriges Radio Play. En amerikansk adhd-coach, Linda Anderson, skapade konceptet bodydoubling på 90-talet. På senare tid har metoden blivit alltmer populär. Metoden går ut på att själva närvaron av en annan person gör det lättare att genomföra vissa uppgifter. Att en annan person finns med i rummet, eller i tanken, gör att fokus ökar och det blir lättare att komma till skott med saker som annars inte blir gjorda. Julia är med i en digital bodydoubling-grupp. Medlemmarna bestämmer tid när en uppgift ska utföras och peppar varandra när de är klara.Sara får besök av sin boendestödjare, Åsa, två timmar i veckan. Att Åsa sitter med gör att Sara tar itu med vardagssysslor som tidigare aldrig blev av. Hon tar tag i sin tvätt och sorterar in i skåpet. Hon kommer iväg till tandläkaren och ringer samtal som hon annars undviker. Medverkande i programmet: Sven Bölte, professor vid Karolinska Institutet,Maria Bühler, psykolog och specialist i neuropsykologi,Åsa Andersen och Johanna Dehlin, boendestödjareProgramledare: Ulrika Hjalmarson NeidemanReportrar: Ninos Chamoun och Simon SarneckiProducent: Stina Näslund

Uppsägningar och oro skakar forskarvärlden i USA en månad efter Trumps återkomst. Hör amerikanska forskares inifrånperspektiv, om vad som hotas. Lyssna på alla avsnitt i Sveriges Radio Play. Vetenskap i osäkra tider – hur påverkas amerikansk forskning?Drygt en månad efter Donald Trumps återkomst till Vita huset skakas den amerikanska forskningsvärlden av nedskärningar, osäkerhet och oro. Stora statliga anslag har frusits eller dragits in, och forskare är rädda för att öppet diskutera situationen.”Kan bli amerikansk brain drain”USA är en världsledande forskningsnation, men vad innebär de senaste politiska besluten för vetenskaplig utveckling? Vi hör oroade amerikanska forskare – hur ser de på framtiden för forskningen i USA och landets utveckling. Nobelpristagare varnar – ”Trump hotar grundforskning”Hör också Victor Ambros, nobelpristagare i medicin 2024, som beskriver hur situationen har blivit värre än han befarade. Han menar att viktiga forskningsområden hotas och att systemet som gjort USA ledande riskerar att falla samman. Hur påverkas grundforskningen när forskare förlorar sin finansiering?Konsekvenser för Sverige och världenDe förändringar som nu sker i USA kan få ringar på vattnet globalt. Vilken roll spelar amerikansk forskning för internationella samarbeten, och vad betyder den nya politiken för Sverige? Hör Marie Arsenian-Henriksson, vicerektor för forskning vid Karolinska Institutet, om utsikterna för deras forskningsprojekt som får medel från USA.Programledare: Björn Gunérbjorn.guner@sr.seProducent: Sara Sällström sara.sallstrom@sr.se

Inger får gå till Mentalvårdsbyrån för att få tillåtelse att avbryta sin graviditet. Ann-Marie löser korsord hemma i sovrummet under sin abort. Lyssna på alla avsnitt i Sveriges Radio Play. Inger Holegård var en av de sista som gjorde abort innan abortlagen trädde i kraft 1975. Hon var 19 år och hade inte kommit igång med sitt vuxna liv när hon upptäckte att hon var gravid. Men för att avsluta graviditeten behöver hon ett godkännande från Mentalvårdsbyrån. När det går igenom är fostret så stort att hon behöver föda fram det på en förlossningsavdelning. Ann-Marie är rädd för att det ska blöda mycket. Linda har gjort två aborter. Första gången blev hon sövd och det gick snabbt. Nästa gång tog det en hel dag av väntan på sjukhuset innan hon var tvungen att skynda hem. Maja gjorde abort när hon var sjutton år och tyckte att undersökningen innan var obehaglig. I år är det femtio år sedan kvinnor i vårt land själva fick möjligheten att bestämma att göra abort innan 18:e graviditetsveckan. Mycket har hänt sedan dess, både i attityder och själva utförandet. Numer är de flesta aborter medicinska. Ingreppet har blivit säkrare och sker alltmer i hemmet istället för på sjukhus. Gäster i programmet är Kristina Gemzell Danielsson, professor i gynekologi och obstetrik vid Karolinska Institutet. Desiree Lichtenstein, läkare o forskare vid Centrum för för epidemiologi och samhällsmedicin, Region Stockholm, Sanna Torén Björling, journalist på DN och USA-korrespondent som skrivit boken “Slaget om aborträtten” och författarduon Malin Clausson och Sandra Pandevski som skrivit boken “50 år av fri abort 50 berättelser”.Programledare Ulrika Hjalmarson NeidemanReportrar: Ninos Chamoun och Olivia SandellProducent: Stina Näslund

Det är ett vanligt missförstånd att människor har lätt att skilja på fakta och värderingar. Beteenden som är vanliga uppfattas oftast dessutom som moraliskt önskvärda, skriver Andreas Olsson, professor i psykologi vid Karolinska Institutet, som undersökt frågan genom vetenskapliga experiment. Inläsare: Staffan Dopping

Aging is a complex process, but have you ever wondered how it differs between men and women? In this week's episode of the Everything Epigenetics podcast, Sara Hägg, an Associate Professor at Karolinska Institutet, and I discuss the fascinating differences in biological aging between sexes. We explore how genetics, hormones, and lifestyle choices contribute to aging disparities and what that means for longevity, disease risk, and overall health.You'll learn about: - How Sara Hägg became interested in aging research and what led her to study sex-specific differences - The major ways men and women age differently at the genetic, molecular, and epigenetic levels - The role of hormones like estrogen and testosterone in shaping the aging process - Why women typically live longer than men and what factors influence this disparity - How stress, diet, and environmental exposures impact aging uniquely for men and women - The latest epigenetic research uncovering biological sex differences in aging - How precision medicine may help tailor aging interventions based on sex-specific needs - Biomarkers of aging and how they reveal crucial insights into longevity and healthspanChapters:00:00 – Introduction to Everything Epigenetics Podcast02:00 – Meet Sara Hägg: Her Background and Research Focus06:30 – What Inspired Her to Study Aging and Sex Differences10:00 – How Do Men and Women Age Differently?15:30 – The Role of Hormones: Estrogen, Testosterone, and Aging20:00 – Why Do Women Live Longer Than Men?26:00 – Cellular and Epigenetic Differences in Male vs. Female Aging30:00 – The Impact of Stress, Diet, and Environment on Aging36:00 – Age-Related Diseases: Which Are More Common in Men vs. Women?40:00 – How Biomarkers Help Predict Aging and Disease Risk45:00 – The Future of Precision Medicine in Aging50:00 – Misconceptions About How Men and Women Age55:00 – Surprising Findings from Sara Hägg's Research58:00 – Closing Thoughts & How to Connect with Sara HäggSupport the showWhere to Find Us:Instagram Twitter Facebook Follow us on:Apple Podcast Spotify YouTube Visit our website for more information and resources: everythingepigenetics.com Thank you for joining us at the Everything Epigenetics Podcast and remember you have control over your Epigenetics, so tune in next time to learn more about how to harness this knowledge for your benefit.

Farewell to an Era: The Final Episode of the Papers PodcastDear Listeners, After more than a decade of insightful discussions, laughter, and learning, we are both excited and a bit teary-eyed to bring you the final episode of the Papers Podcast. This isn't just an episode; it's a heartfelt celebration of our journey together. From our humble beginnings recording in hotel rooms to becoming a beloved source of knowledge and camaraderie in the medical education community, we've cherished every moment with you.In this special farewell episode, join Jason, Jonathan, Lara, and Linda as they reflect on the incredible progress in our field, share personal anecdotes, and express their deepest gratitude to you, our loyal listeners. We've laughed, we've learned, and we've grown together, and now it's time to reminisce about the highlights and the friendships that have made this journey unforgettable. Whether you've been with us from the start or joined us along the way, this episode is a tribute to you. So, grab your favorite beverage, settle in, and let's take one last stroll down memory lane together. Thank you for being part of our story. We couldn't have done it without you.With heartfelt thanks and warmest regards,The Papers Podcast Team.Papers Podcast Episode website.PAPERs Podcast are:Hosts: Lara Varpio, Jason Frank, Jonathan Sherbino, Linda Snell.Technical Producer: Samuel Lundberg.Web Manager: Alex Alexandersson.Executive Producer: Teresa Sörö.This is a production from Karolinska Institutet.

How can we make assessments truly equitable? In this episode, Lara dives into a paper that explores fairness, inclusion, and justice as three distinct approaches to equity in assessment. Discover how these orientations can reshape our goals, strategies, and impact in education. This episode unpacks critical frameworks that empower educators to reflect on critically and reimagine assessment systems.Episode host: Lara Varpio.Episode article:Anderson, H. L. K., Govaerts, M., Abdulla, L., Balmer, D. F., Busari, J. O., & West, D. C. (2024). "Clarifying and expanding equity in assessment by considering three orientations: Fairness, inclusion and justice". Medical Education, Advance online publication.You can find episode notes and other resources on the Papers Podcast episode website.PAPERs Podcast are:Hosts: Lara Varpio, Jason Frank, Jonathan Sherbino, Linda SnellTechnical Producer: Samuel LundbergWeb Manager: Alex AlexanderssonExecutive Producer: Teresa SöröProduction of Teaching and Learning at Karolinska Institutet

Around the world, prison populations are bursting at the seams, but in some European countries, they are closing and reoffending rates are down. The trend has been attributed to a novel approach to justice, one that places the mental health of offenders at its heart. Forensic psychologist Dr Jenny Okolo investigates whether prison systems around the world could benefit from a similar approach. Jenny speaks to Dr Marrit de Vries from the Dutch Institute for Forensic Psychiatry and Psychology, to learn about a novel approach to mental health intervention pioneered in the Netherlands. And in Sweden, we hear from Dr Martin Lardén from Karolinska Institutet's Center for violence prevention, who discusses the efficacy of the Risk-Need-Responsivity model, an approach which positions the offender at the heart of the strategies devised to address the causes of their crime. And Rivelino Rigters, who draws on lived experience from within the criminal justice system, reflects on how a kinder, community-focused approach could stop crime from happening in the first place.

Welcome to a special Holiday Episode of the PAPERs Podcast! In this fun and festive episode, the hosts bring their quirkiest and most unconventional academic papers to the table, sharing surprising insights and plenty of laughs along the way. The hosts have scoured the academic universe to bring you the following:  How alcohol might just help you solve creative problems.Why eating chocolate could potentially make you a Nobel laureate.How side effects of placebos can enhance their perceived effectiveness.The surprising connection between video games and bronchoscopy skills.Why humor belongs in the classroom, straight from medical students' perspectives.Insights into how science progresses—one funeral at a time.You find episode notes and references at the episode webpagePAPERs Podcast areHosts: Lara Varpio, Jason Frank, Jonathan Sherbino, Linda SnellTechnical Producer: Samuel LundbergWeb Manager: Alex AlexanderssonExecutive Producer: Teresa SöröProduction of Unit for teaching and learning at Karolinska Institutet

#76 – A review on modern teaching and learning techniques in medical educationAre your students truly engaged? In this episode, the hosts dive into a micro-monograph that shakes up stale teaching techniques by showcasing fresh, student-centered methods that go way beyond the classic lecture snooze-fest. With plenty of laughs and a dash of nostalgia, they share their own teaching experiments, swapping old-school habits for bold, adaptable approaches to keep both educators and students on their toes in today's fast-evolving medical world.Episode host: Jonathan Sherbino.Episode article:Karkera S, Devendra N, Lakhani B, Manahan K, Geisler J. "A review on modern teaching and learning techniques in medical education". EIKI Journal of Effective Teaching Methods. 2024 Jan 26;2(1). You find episode notes and other resources at the Papers Podcast episode website.PAPERs Podcast are:Hosts: Lara Varpio, Jason Frank, Jonathan Sherbino, Linda SnellTechnical Producer: Samuel LundbergWeb Manager: Alex AlexanderssonExecutive Producer: Teresa SöröProduction of Teaching and Learning at Karolinska Institutet

#75 - Hot for TeacherAre we all insane? Given all the contemporary challenges and frictions at work, why do we teach?This episode unpacks the critical factors behind teacher motivation and delivers evidence-based strategies to inspire, recruit, and retain top educators in the health professions using Self Determination Theory.Episode host: Jason R. Frank.Episode article: Orsini, C., Imafuku, R., Jennings, B., Neufeld, A., Tricio, J., & Kusurkar, R. A. (2024). What influences clinical educators' motivation to teach? A BEME systematic review and framework synthesis based on self-determination theory: BEME Review No. 90. Medical Teacher, 1–9.You find episode notes and other resources at the Papers Podcast episode website.PAPERs Podcast are:Hosts: Lara Varpio, Jason Frank, Jonathan Sherbino, Linda SnellTechnical Producer: Samuel LundbergWeb Manager: Alex AlexanderssonExecutive Producer: Teresa SöröProduction of Teaching and Learning at Karolinska Institutet

Feeling lost in the world of literature reviews?Choosing the right type can be overwhelming, from systematic to scoping, realist to narrative. In this episode, Lara breaks it down with clarity. Learn how to navigate the objectivist–subjectivist continuum, align your review to your research goals, and uncover tools that make the process easier. Whether you're a beginner or a seasoned researcher, this guide is your roadmap to impactful literature reviews.Episode host: Lara VarpioYou find episode notes and references at the episode webpagePAPERs Podcast areHosts: Lara Varpio, Jason Frank, Jonathan Sherbino, Linda SnellTechnical Producer: Samuel LundbergWeb Manager: Alex AlexanderssonExecutive Producer: Teresa SöröProduction of Unit for teaching and learning at Karolinska Institutet

Ever wondered how your first impressions as a clinical supervisor shape your evaluations? This episode uncovers the findings from a recent study on the role of first impressions in performance-based assessments. Learn how explicit and implicit biases can affect your judgment and what you can do to ensure fair and accurate evaluations. Don't miss this essential discussion on improving your assessment practices!Episode host: Linda SnellYou can find episode notes and resources at the Papers Podcast episode website.Episode article:Wood, T. J., Daniels, V. J., Pugh, D., Touchie, C., Halman, S., & Humphrey-Murto, S. (2024). Implicit versus explicit first impressions in performance-based assessment: Will raters overcome their first impressions when learner performance changes? Advances in Health Sciences Education, 29(4), 1155–1168.PAPERs Podcast are:Hosts: Lara Varpio, Jason Frank, Jonathan Sherbino, Linda SnellTechnical Producer: Samuel LundbergWeb Manager: Alex AlexanderssonExecutive Producer: Teresa SöröProduction of Teaching and Learning at Karolinska Institutet